Current Clinical Trials

Novartis are currently conducting a clinical research study to find out if the drug secukinumab is safe and has beneficial effects in people who have moderate to severe hidradenitis suppurativa.

The study is being carried out in hospitals across the world, including hospitals in the UK. Approximately 471 patients will take part worldwide, with approximately 48 being in the UK. The study consists of a screening period (up to 4 weeks), treatment period 1 (16 weeks, active drug or placebo) and treatment period 2 (up to 1 year all patients on active drug).

Adult males and females with moderate to severe HS will be included, with a diagnosis of HS greater than 1 year. Dosing will be once every 2 weeks, or once every 4 weeks via pre-filled syringe; periodic home-dosing is included. The primary objective is to demonstrate the efficacy of secukinumab compared to placebo.

If you would like to hear more about this study or wish to be considered for participation, please contact your nearest participating hospital below.